伊立替康联合顺铂治疗56例晚期非小细胞肺癌疗效及毒副反应观察

Observation of Clinical efficacy and toxicity on irinotecan plus cisplatin for 56 patients in advanced non-small cell lung cancer

目的 采用前瞻性、开放性的临床研究探讨伊立替康联合顺铂（IP）一线治疗NSCLC的近期疗效和毒副反应.方法 连续选择经组织学或细胞学确诊的初治晚期NSCLC患者56例,按CPT-11 100mg/m2,第一、八天;顺铂25mg/m2,第一～三天;每21d为1周期,至少2周期以上可评价疗效及不良反应.结果 全组PR 27例,SD 16例,PD 13例,有效率48.1%,中位生存期为11.2月,PFS时间为4.44±2.39个月.主要毒副反表现为迟发性腹泻及骨髓抑制.结论 伊立替康联合顺铂治疗晚期NSCLC期疗效确切,毒副反应安全可耐受.

OBJECTIVE To prospectively evaluate the efficacy and toxicity of irinotecan plus cisplatin （ IP regi- men） as the first-line treatment in advanced non-small cell lung cancer（NSCLC）. METHODS 56 advanced non- small cell lung cancer patients who were confirmed by histology and cytology were enrolled. IP regime was treated with cisplatin 25mg/m2 on first day to three day plus irinotecan 100mg/m2 on first day, eight day every 3weeks. The efficacy and toxicity were evaluated after at least 2 cycles of chemontherapy given. RESULTS The total RR was 48. 1% ,27 patients had PR, 16 patients with SD and I3 patients with PD. Median survival time was 11.2months and Progression-free survival time was 4.44 ± 2. 39 month. The major toxicities was delayed diarrhea and myelosuppres- sion. CONCLUSION irinotecan plus cisplatin regimen have specific efficacy as the first-line treatment to advanced non-small cell lung cancer. The major toxicities were be well tolerated and safety.